Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: PIERRE FABRE DERMATOLOGIE, 45 place Abel Gance, F-92100 Boulogne
HEMANGIOL 3.75 mg/mL oral solution.
Pharmaceutical Form |
---|
Oral solution. Clear, colourless to slightly yellow oral solution, with a fruity odour. |
1 ml of solution contains 4.28 mg of propranolol hydrochloride equivalent to 3.75 mg of propranolol base.
Excipients with known effect: 1 ml of solution contains Propylene glycol 2.60 mg.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Propranolol |
Propranolol is a competitive antagonist at both beta, and beta2-adrenoceptor, but has membrane stabilising activity at concentrations exceeding 1-3mg/litre, though such concentrations are rarely achieved during oral therapy. Competitive beta-blockade has been demonstrated in man by a parallel shift to the right in the dose-heart rate response curve to beta-agonists such as isoprenaline. |
List of Excipients |
---|
|
120 mL solution, in a type III amber-glass bottle fitted with a low density polyethylene insert and a child resistant polypropylene screw cap, provided with a polypropylene oral syringe graduated in mg of propranolol base.
Pack size: carton containing 1 bottle and 1 oral syringe.
PIERRE FABRE DERMATOLOGIE, 45 place Abel Gance, F-92100 Boulogne
EU/1/14/919/001
Date of first authorisation: 23 April 2014
Drug | Countries | |
---|---|---|
HEMANGIOL | Austria, Canada, Estonia, Spain, Finland, France, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, Turkey |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.